Federal health firms on Tuesday suggested a time out on administering the Johnson & & Johnson single-dose vaccine while they dig deeper into reports from numerous ladies in between the ages of 18 and 48 who said they fell ill with “a severe and unusual kind of blood embolisms”– as explained by the CDC– within two weeks of getting the vaccine. One of the ladies passed away.
Nearly 7 million doses of the vaccine have actually been administered in the U.S.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The CDC is set to convene a conference on Wednesday to examine the cases.
In a statement, Johnson & & Johnson said the health and safety of people who utilize its items is its number one top priority.
CLICK HERE TO READ MORE ON FOX BUSINESS
Even without Johnson & & Johnsons vaccine, White House officials stated they remain on track to have sufficient materials to vaccinate most American adults by the summer season.
“We think theres adequate vaccine in the system– Moderna and Pfizer– for all Americans who want to get vaccinated by May 31 to do so,” stated Jeff Zients, the White Houses COVID-19 action coordinator.
The Associated Press contributed to this report.
The additional dosages of Pfizer might help balance out a possible reduction in expected vaccine doses, depending upon what health authorities choose to do with the Johnson & & Johnson vaccine moving forward.
Moderna Inc. likewise responded to the Johnson & & Johnson problems, emphasizing the safety of its vaccine.
BENEFITS OF JOHNSON & & JOHNSON VACCINE STILL OUTWEIGH THE RISKS: DR. NESHEIWAT
Pharmaceutical giant Pfizer stated Tuesday that it is prepared to ramp up production of its COVID-19 vaccine after U.S. federal agencies advised a pause on administering injections of the Johnson & & Johnson variation over health dangers.
In a Twitter post, Pfizer CEO Albert Bourla said the business can provide 10% more dosages than formerly concurred to– an overall of 220 million– by the end of May. He likewise stated Pfizer will have the complete 300 million doses scheduled for delivery in the U.S. by the end of July, two weeks early.
Dr. Bob Lahita talks about the probability of experiencing threats from the Johnson & & Johnson vaccine, as the government stops its rollout.